These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 18358721)
21. Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole. Lee SH; Kim S; Yun MH; Lee YS; Cho SN; Oh T; Kim P Bioorg Med Chem Lett; 2011 Mar; 21(5):1515-8. PubMed ID: 21277200 [TBL] [Abstract][Full Text] [Related]
22. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles. Walczak K; Gondela A; Suwiński J Eur J Med Chem; 2004 Oct; 39(10):849-53. PubMed ID: 15464618 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168 [TBL] [Abstract][Full Text] [Related]
26. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Singh R; Manjunatha U; Boshoff HI; Ha YH; Niyomrattanakit P; Ledwidge R; Dowd CS; Lee IY; Kim P; Zhang L; Kang S; Keller TH; Jiricek J; Barry CE Science; 2008 Nov; 322(5906):1392-5. PubMed ID: 19039139 [TBL] [Abstract][Full Text] [Related]
28. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. Hurdle JG; Lee RB; Budha NR; Carson EI; Qi J; Scherman MS; Cho SH; McNeil MR; Lenaerts AJ; Franzblau SG; Meibohm B; Lee RE J Antimicrob Chemother; 2008 Nov; 62(5):1037-45. PubMed ID: 18693235 [TBL] [Abstract][Full Text] [Related]
29. Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Anderson RF; Shinde SS; Maroz A; Boyd M; Palmer BD; Denny WA Org Biomol Chem; 2008 Jun; 6(11):1973-80. PubMed ID: 18480913 [TBL] [Abstract][Full Text] [Related]
31. Alkylated/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: Synthesis and anti-mycobacterial evaluation. Shalini ; Viljoen A; Kremer L; Kumar V Bioorg Med Chem Lett; 2018 May; 28(8):1309-1312. PubMed ID: 29551480 [TBL] [Abstract][Full Text] [Related]
32. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Denny WA; Palmer BD Future Med Chem; 2010 Aug; 2(8):1295-304. PubMed ID: 21426020 [TBL] [Abstract][Full Text] [Related]
33. 1,3-Oxazine-2-one derived dual-targeted molecules against replicating and non-replicating forms of Mycobacterium tuberculosis. Velappan AB; Kesamsetty D; Datta D; Ma R; Hari N; Franzblau SG; Debnath J Eur J Med Chem; 2020 Dec; 208():112835. PubMed ID: 32977201 [TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Ashtekar DR; Costa-Perira R; Nagrajan K; Vishvanathan N; Bhatt AD; Rittel W Antimicrob Agents Chemother; 1993 Feb; 37(2):183-6. PubMed ID: 8452346 [TBL] [Abstract][Full Text] [Related]
35. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives. Gonçalves RS; Kaiser CR; Lourenço MC; de Souza MV; Wardell JL; Wardell SM; da Silva AD Eur J Med Chem; 2010 Dec; 45(12):6095-100. PubMed ID: 20932608 [TBL] [Abstract][Full Text] [Related]
37. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332 [TBL] [Abstract][Full Text] [Related]